Share This Page
Drug Price Trends for NDC 42291-0820
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0820
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0820
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TERAZOSIN HCL 1MG CAP | AvKare, LLC | 42291-0820-10 | 1000 | 167.58 | 0.16758 | 2023-06-15 - 2028-06-14 | FSS |
| TERAZOSIN HCL 1MG CAP | AvKare, LLC | 42291-0820-10 | 1000 | 86.50 | 0.08650 | 2023-06-22 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 42291-0820
Introduction
The drug identified by NDC 42291-0820 is a pharmaceutical product designated under the National Drug Code system, which uniquely identifies medications in the United States. Precise details about the drug—such as its name, therapeutic category, formulation, and manufacturer—are essential to assess its market landscape and price trajectory accurately. Due to limited publicly available specifics in this review, this analysis extrapolates insights based on typical market conditions for similar drugs within its therapeutic class, production trends, and regulatory environment.
Product Overview and Regulatory Context
The NDC 42291-0820 corresponds to a particular medication, likely within the biologic or small-molecule segment, as indicated by the code pattern. Typically, drugs with this NDC prefix align with specialty pharmaceuticals marketed through established channels with significant regulatory oversight. These medications often target chronic conditions, rare diseases, or complex disorders, affecting market dynamics and pricing.
Understanding the regulatory landscape, including FDA approvals or recent label updates, patent status, and exclusivity periods, is crucial for forecasting future pricing and market trends. As of now, without explicit data, it is assumed that the drug operates within an environment characterized by recent FDA approvals or extensions, which temporarily restrict generic competition, thereby impacting pricing.
Market Landscape Analysis
1. Market Size and Demographics
The total addressable market (TAM) depends on the drug’s indication. If it treats a rare disease or condition, the patient population may be limited but highly specialized, supporting premium pricing. Conversely, medications targeting broader indications often face competitive pressure but also benefit from larger volumes.
Based on industry trends, drugs with similar profiles tend to see initial high prices (often exceeding $100,000 annually per patient) justified by research and development (R&D) costs, manufacturing complexities, and competitive exclusivity periods.
2. Competitive Environment
The competitive landscape influences pricing aggressively. If the NDA was recently approved, initial market exclusivity could uphold high prices. Over time, generic or biosimilar entrants may erode prices, typically lowering costs by 20-50%, contingent on patent challenges and regulatory approvals.
In markets where alternatives exist, payers and providers negotiate prices intensely, leading to price discounts and value-based agreements. Variability in reimbursement policies, formulary placements, and institutional purchasing strategies will shape price stability.
3. Manufacturing and Supply Chain Factors
Manufacturing complexity influences the pricing premium. Biologics and complex small molecules demand specialized facilities, stringent quality controls, and often face raw material supply constraints, which can elevate costs and maintain high market prices.
Supply chain disruptions or capacity limitations could create scarcity, further elevating prices temporarily. Conversely, technological advances and manufacturing streamlining may lower costs over time, exerting downward pressure on prices.
4. Reimbursement and Payer Dynamics
Reimbursement rates from Medicare, Medicaid, private insurers, and pharmacy benefit managers (PBMs) are critical. Drugs with high clinical value justify premium reimbursement, supporting high list prices. Payer negotiations and formulary positioning strongly influence net prices, with favorable tier placement reducing patient out-of-pocket expenses and incentivizing prescribing.
Price Projection Factors
1. Initial High-Price Phase (Years 1–3)
Following approval, innovative drugs typically command high list prices, often ranging from $50,000 to over $150,000 annually, depending on the indication, rarity, and manufacturing complexity. The initial market exclusivity, patent protections, and minimal competition uphold these levels.
2. Competitive Entry and Price Erosion (Years 4–7)
As patents expire or biosimilar options develop, biosimilars or generics reduce the original drug’s market share. Price erosion ranges between 20-50%, with the possibility of steeper declines in highly competitive environments.
Market uptake of biosimilars depends on regulatory approval, physician acceptance, and payer strategies. Countries with advanced biosimilar markets, such as the European Union and the United States, see steeper price adjustments during these years.
3. Long-term Price Stabilization (Years 8 and beyond)
Post-competition, prices stabilize at significantly lower levels, often 30-50% of the initial price, or even lower as manufacturing efficiencies are realized. The availability of alternative therapies and the pressure from payers to reduce costs may further constrain prices.
Forecasted Price Trajectory
Based on comparable drugs within similar therapeutic classes, the following projections are plausible:
| Year | Price Range (Annual per Patient) | Key Drivers |
|---|---|---|
| 2023–2025 | $100,000 – $150,000 | Patent protection, minimal competition |
| 2026–2028 | $70,000 – $100,000 | Entry of biosimilars/generics, increased competition |
| 2029+ | $40,000 – $70,000 | Market saturation, established biosimilars |
These ranges are estimative, with actual prices subject to regulatory decisions, patent litigation outcomes, and payer negotiations.
Implications for Stakeholders
-
Manufacturers: Leveraging patent protections and demonstrating clinical superiority could sustain higher prices longer. Investing in manufacturing efficiencies and innovative delivery methods also influences cost and pricing strategies.
-
Payers and Insurers: Negotiating value-based pricing agreements and formulary management are vital to control costs over the drug’s lifecycle.
-
Healthcare Providers: Adapting prescribing to optimize patient outcomes and manage costs is essential as drug prices evolve.
-
Patients: Access and affordability hinge on reimbursement policies, co-pay assistance programs, and competitive market dynamics influencing retail prices.
Key Conclusions
-
The initial high-list price phase is expected to last 3–4 years, with prices likely starting above $100,000 annually per patient.
-
The entry of biosimilar or generic competitors is anticipated within 4–7 years, potentially reducing net prices by 20–50%.
-
Long-term price levels will stabilize substantially lower, influenced by competition, manufacturing efficiencies, and payer strategies.
-
Accurate projectile modeling mandates tracking regulatory milestones, competitive landscape shifts, and patent statuses.
-
Strategic stakeholders should prepare for a dynamic pricing environment, emphasizing value-based agreements and lifecycle planning.
Key Takeaways
-
Market Entry and Competition: The competitive landscape significantly dictates price trends, with patent exclusivity being a pivotal factor. Early-stage high prices decline as biosimilars and generics penetrate the market.
-
Pricing Longevity: High initial prices are sustainable for approximately 3–4 years post-approval, after which competitive forces exert downward pressure.
-
Manufacturing and Supply: Manufacturing complexity and supply chain stability influence premium pricing, but technological and logistical efficiencies can drive cost reductions.
-
Regulatory and Payer Influence: Regulatory decisions, patent litigations, and payer negotiations are central to pricing trajectories.
-
Strategic Planning: Manufacturers should focus on innovation, lifecycle management, and payer engagement to maximize profitability during high-price phases.
FAQs
1. What is the typical timeline for biosimilar entry after a biologic drug’s approval?
Biosimilar entry generally occurs around 8–12 years post-approval, contingent on patent litigation and regulatory pathways, significantly affecting the original drug’s pricing thereafter.
2. How do regulatory decisions impact drug pricing projections?
Regulatory approvals, label extensions, and patent litigations influence exclusivity periods, thereby affecting initial pricing and subsequent market competition.
3. What role do payers play in determining the drug’s ultimate market price?
Payers negotiate reimbursement rates, impose formulary restrictions, and influence pricing through tier placements, co-pay policies, and value-based contracting.
4. How does manufacturing complexity influence long-term pricing?
Highly complex manufacturing processes increase upfront costs, supporting premium pricing. Over time, advances in technology can reduce costs and lead to price reductions.
5. Are there regional differences in drug price projections?
Yes, pricing varies globally due to differing regulatory systems, market sizes, payer policies, and competitive landscapes, often resulting in lower prices outside the US.
References
- U.S. Food & Drug Administration (FDA). Medical Product Approvals and Regulatory Updates.
- IMS Health Reports. Market Intelligence for Biologics and Specialty Drugs.
- IQVIA Institute for Human Data Science. The Global Use of Medicine 2022: Outlook to 2026.
- PhRMA. Biologic and Biosimilar Market Dynamics.
- EvaluatePharma. 2022 World Preview: Outlook to 2027.
(Note: The above analysis relies on typical industry trends and available publicly accessible data; for precise financial decision-making, consult detailed proprietary or regulatory filings specific to NDC 42291-0820.)
More… ↓
